vrn101099
HER2-positive Solid Tumors
Voronoi, IncPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
0 Active assets in the HER2-positive Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
kn046 Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 | B |
ANTI-HER2 BSAB KN026 Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 | B |
Trastuzumab Imbotolimod Bolt Biotherapeutics, Inc. | Phase 1/2 | CC |
Nivolumab Bolt Biotherapeutics, Inc. | Phase 1/2 | CC |
Epirubicin Carisma Therapeutics Inc | Phase 1 | CC |
Cyclophosphamide Carisma Therapeutics Inc | Phase 1 | CC |
ct-0508 Carisma Therapeutics Inc | Phase 1 | CC |
Pembrolizumab Carisma Therapeutics Inc | Phase 1 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →